First patient dosed in Phase I clinical trial of CHECKvacc
Filed with ASX · · 5 pages · English
Story so far
Earlier from Imugene
- Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
- S&P DJI Announces September 2021 Quarterly Rebalance
- Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
- Appendix 4E and Full Year Statutory Accounts
- Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
Later from Imugene
- Investor Presentation Imugene Eureka Therapeutics
- Clinical Trial Supply Agreement with Merck KGaA and Pfizer
- S&P DJI Announces December 2021 Quarterly Rebalance
- Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
- FDA IND approval for the phase 2 clinical trial of HER-Vaxx
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene